Moderate hypofractionation for prostate cancer: A user's guide

Moderate hypofractionation for prostate cancer

At the end of the last century, Brenner and Hall [1] argued that the fractionation sensitivity of prostate cancer was different from most tumors and normal tissues, with the opportunity to increase the therapeutic ratio by treating this cancer with hypofractionation (fewer, larger daily fractions). Nearly two decades later, the use of moderate hypofractionation for prostate cancer has become an...

Hypofractionation trials and radiobiology of prostate cancer

Hypofractionation: what does it mean for prostate cancer treatment?

PURPOSE Using current radiobiologic models and biologic parameters, we performed an exploratory study of the clinical consequences of hypofractionation in prostate cancer radiotherapy. METHODS AND MATERIALS Four hypofractionated treatment regimens were compared with standard fractionation of 2 Gy x 39 for prostate carcinoma using a representative set of anatomical structures. The linear-quadr...

Prostate cancer and hypofractionation: really a new standard of care?

The Lancet Oncology published in June 2016 results of the CHHiP trial (1): a randomized phase 3, non-inferiority trial testing a standard radiotherapy treatment for localized prostate cancer (74 Gy in 37 fractions over 7.4 weeks) compare to two more protracted schedules: 60 Gy in 20 fractions/4 weeks or 57 Gy in 19 fractions/3.8 weeks. The majority of enrolled patients had low or intermediate-r...

Hypofractionation for prostate cancer radiotherapy--what are the issues?

2. It is generally assumed that the mechanistic basis for the different fractionation response of tumors and late-responding normal tissues relates to the larger proportion of cycling cells in tumors. However, prostate tumors contain unusually small fractions of cycling cells (19), so back in 1999, Brenner and Hall (1) and Duchesne and Peters (2) reasoned that prostate tumors might not respond ...